Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation
Jinyun Dong, Xiangdong Cheng, Weidong Zhang, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 13, pp. 8884-8915
Closed Access | Times Cited: 132

Showing 51-75 of 132 citing articles:

Structure, function, signaling pathways and clinical therapeutics: The translational potential of STAT3 as a target for cancer therapy
Dandan Shi, Jiejing Tao, Shuli Man, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 6, pp. 189207-189207
Closed Access | Times Cited: 2
Acacetin Inhibits the Growth of STAT3-Activated DU145 Prostate Cancer Cells by Directly Binding to Signal Transducer and Activator of Transcription 3 (STAT3)
Yun Sun, Yu-Jin Lee, Jiyeon Choi, et al.
Molecules (2021) Vol. 26, Iss. 20, pp. 6204-6204
Open Access | Times Cited: 20
Insights into the role of STAT3 in intrahepatic cholangiocarcinoma (Review)
Ranzhiqiang Yang, Yinghui Song, Kashif Shakoor, et al.
Molecular Medicine Reports (2022) Vol. 25, Iss. 5
Open Access | Times Cited: 14
S3I-201 derivative incorporating naphthoquinone unit as effective STAT3 inhibitors: Design, synthesis and anti-gastric cancer evaluation
Haobin Li, Mao-Hua Cai, Fei Cao, et al.
Bioorganic & Medicinal Chemistry (2022) Vol. 71, pp. 116941-116941
Closed Access | Times Cited: 14
Discovery of STAT3 Inhibitors: Recent Advances and Future Perspectives
Jiatao Song, Jiawei Wang, Sheng Tian, et al.
Current Medicinal Chemistry (2022) Vol. 30, Iss. 16, pp. 1824-1847
Closed Access | Times Cited: 14
Small-Molecule PROTACs for Cancer Immunotherapy
Zefan Liu, Yajun Zhang, Yucheng Xiang, et al.
Molecules (2022) Vol. 27, Iss. 17, pp. 5439-5439
Open Access | Times Cited: 14
Design, synthesis, and biological characterization of a potent STAT3 degrader for the treatment of gastric cancer
Haobin Li, Lingling Wang, Fei Cao, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 13
Discovery of a Novel Potent STAT3 Inhibitor HP590 with Dual p-Tyr705/Ser727 Inhibitory Activity for Gastric Cancer Treatment
Peng He, Ying Miao, Yue Sun, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 19, pp. 12650-12674
Closed Access | Times Cited: 13
Non-coding RNAs and exosomal ncRNAs in multiple myeloma: An emphasis on molecular pathways
Mehrdad Hashemi, Sophie Mousavian Roshanzamir, Mahshid Deldar Abad Paskeh, et al.
European Journal of Pharmacology (2023) Vol. 941, pp. 175380-175380
Closed Access | Times Cited: 6
Eupalinolide J Inhibits Cancer Metastasis by Promoting STAT3 Ubiquitin-Dependent Degradation
Hongtao Hu, Haoyang Bai, Lili Huang, et al.
Molecules (2023) Vol. 28, Iss. 7, pp. 3143-3143
Open Access | Times Cited: 6
Design, synthesis, and biological evaluation of novel napabucasin-melatonin hybrids as potent STAT3 inhibitors
Chong Zhang, Limin Yang, Xiaojuan Yang, et al.
Bioorganic Chemistry (2023) Vol. 136, pp. 106541-106541
Closed Access | Times Cited: 6
Inonotsutriol E from Inonotus obliquus exhibits promising anti breast cancer activity via regulating the JAK2/STAT3 signaling pathway
Peipei Shan, Chao Wang, Honglei Chen, et al.
Bioorganic Chemistry (2023) Vol. 139, pp. 106741-106741
Closed Access | Times Cited: 6
The self-adjuvant heterocyclic lipid nanoparticles encapsulated with vaccine and STAT3 siRNA boost cancer immunotherapy through DLN-targeted and STING pathway
Zixu Liu, Qingqing Wang, Yu-Peng Feng, et al.
Chemical Engineering Journal (2023) Vol. 475, pp. 146474-146474
Closed Access | Times Cited: 6
SHF Acts as a Novel Tumor Suppressor in Glioblastoma Multiforme by Disrupting STAT3 Dimerization
Jingjing Wang, Zixuan Huang, Ji Li, et al.
Advanced Science (2022) Vol. 9, Iss. 26
Open Access | Times Cited: 11
Discovery of a Highly Potent and Orally Bioavailable STAT3 Dual Phosphorylation Inhibitor for Pancreatic Cancer Treatment
Peng He, Aiwu Bian, Ying Miao, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 22, pp. 15487-15511
Closed Access | Times Cited: 11
The direct STAT3 inhibitor 6-ethoxydihydrosanguinarine exhibits anticancer activity in gastric cancer
Xuewen Liu, Xin Jin, Hongling Ou, et al.
Acta Materia Medica (2022) Vol. 1, Iss. 3
Open Access | Times Cited: 10
miR-330-5p Suppress Cell Growth and Invasion via Disrupting HSF4-mediated MACC1/STAT3 Pathway in Colorectal Cancer
Jinghua Liu, Kelin Yue, Junya Yang, et al.
Frontiers in Bioscience-Landmark (2024) Vol. 29, Iss. 2, pp. 53-53
Open Access | Times Cited: 1
Research on the signaling pathways related to the intervention of traditional Chinese medicine in Parkinson's disease:A literature review
Xiaxia Jin, Wendi Dong, Kaile Chang, et al.
Journal of Ethnopharmacology (2024) Vol. 326, pp. 117850-117850
Closed Access | Times Cited: 1
Enhancing cancer therapy: The role of drug delivery systems in STAT3 inhibitor efficacy and safety
Kangning Wang, Kan Zhou, Nian‐Nian Zhong, et al.
Life Sciences (2024) Vol. 346, pp. 122635-122635
Closed Access | Times Cited: 1
The Janus kinase 1 is critical for pancreatic cancer initiation and progression
Hridaya Shrestha, Patrick D. Rädler, Rayane Dennaoui, et al.
Cell Reports (2024) Vol. 43, Iss. 5, pp. 114202-114202
Open Access | Times Cited: 1
Synthesis and pharmacological evaluation of polyamine-diarylidenyl piperidone derivatives as potent antitumor agents
Zhi-Chen Mao, Shuang-Qiang Liu, Xiao-Man Chen, et al.
Monatshefte für Chemie - Chemical Monthly (2024) Vol. 155, Iss. 7, pp. 747-753
Closed Access | Times Cited: 1
The molecular effects underlying the pharmacological activities of daphnetin
Zhifeng Wei, Na Wei, Long Su, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 1
Eugenol suppresses VEGF-dependent angiogenesis by JAK2/STAT3 pathway in non-small cell lung cancer
Yifan Su, Yurong Wang, Qian Yu, et al.
Deleted Journal (2024) Vol. 2, Iss. 2, pp. 80-90
Closed Access | Times Cited: 1
Small molecular inhibitors and degraders targeting STAT3 for cancer therapy: An updated review (from 2022 to 2024)
Zhaoyong Kang, Li Shen, Yan Li, et al.
Chinese Chemical Letters (2024), pp. 110447-110447
Closed Access | Times Cited: 1
Epithelial–mesenchymal transition to Mitigate Age-Related Progression in Lung Cancer
Riya Thapa, Saurabh Gupta, Gaurav Gupta, et al.
Ageing Research Reviews (2024) Vol. 102, pp. 102576-102576
Closed Access | Times Cited: 1

Scroll to top